Top Bull Pitch

Submitted January 20, 2014

A nice uptick in quarterly revenues wasn't enough to keep Derma from sliding into the end of 2013 on a downward note. Their main issue has been difficulty enrolling their phase III trials of DSC127 for diabetic foot ulcers, which is somewhat… More